Related Experiment Video

Updated: Aug 24, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

The inhibition of tumor growth by triplex-forming oligonucleotides

Richard N Re1, Julia L Cook, Jason F Giardina

  • 1Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121, USA. rre@ochsner.org

Cancer Letters
|May 18, 2004
PubMed

Insights

A novel triplex-forming oligonucleotide targeting the p53 binding site significantly inhibited colon cancer tumor growth in mice. This DNA-based therapy shows promise for in vivo cancer treatment, reducing tumor size compared to controls.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Oligonucleotides targeting p53 binding sites inhibit colon cancer cell proliferation in vitro.
  • Previous research established the in vitro efficacy of triplex-forming oligonucleotides against colon cancer.

Purpose of the Study:

  • To evaluate the in vivo efficacy of a triplex-forming oligonucleotide (Hoog1) in a mouse model of human colon cancer.
  • To determine if Hoog1 can inhibit tumor growth in a subcutaneous xenograft model.

Main Methods:

  • HCT 116 human colon carcinoma cells were implanted subcutaneously in Ncr nude mice.
  • Established tumors were treated daily for 14 days with Hoog1, a scrambled control oligonucleotide (Hoog3), or vehicle.
  • Tumor size was measured twice weekly to assess growth inhibition.

Main Results:

  • The active triplex-forming oligonucleotide (Hoog1) significantly reduced tumor size compared to both the scrambled control (Hoog3) and vehicle groups.
  • Statistical analysis confirmed significant differences in tumor sizes among the three groups (P < 0.001).
  • Post-hoc tests indicated significant differences between the Hoog1 group and each control group (P < 0.05).

Conclusions:

  • A triplex-forming oligonucleotide targeting a p53 consensus binding site effectively reduces tumor growth in an in vivo colon cancer model.
  • This suggests a novel therapeutic strategy for inhibiting tumor development using DNA-based interventions.
  • The findings support further investigation of triplex oligonucleotides as a potential anti-cancer treatment.

More Related Videos

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks12:19

Tools to Study the Role of Architectural Protein HMGB1 in the Processing of Helix Distorting, Site-specific DNA Interstrand Crosslinks

Published on: November 10, 2016

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by Gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles

Published on: March 18, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...